LGALS9 and pancreatic neoplasm: Similarly, bone marrow mesenchymal stem cell exosomes co-loaded with Galectin-9 siRNA and oxaliplatin reverse the immunosuppressive phenotype of TAMs by blocking the Galectin-9/Dectin-1 axis and induce immunogenic cell death in tumor cells, synergistically improving immunotherapy efficacy in pancreatic cancer (302).